Preferred Label : lanadelumab;

Details


Keyword's position in hierarchy(ies) : arborescence

Main resources

You can consult :


https://www.has-sante.fr/jcms/p_3201790
2020
France
evaluation of the transparency committee
lanadelumab
Takhzyro
lanadelumab

---
https://www.has-sante.fr/portail/jcms/c_2973363/fr/takhzyro
2019
false
false
false
France
French
lanadelumab
lanadelumab
injections, subcutaneous
treatment outcome
angioedemas, hereditary
recurrence
adolescent
adult
aged
orphan drug production
evaluation of the transparency committee
lanadelumab
antibodies, monoclonal

---
https://www.ema.europa.eu/en/medicines/human/EPAR/takhzyro
2018
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug approval
europe
lanadelumab
lanadelumab
lanadelumab
orphan drug production
adolescent
adult
angioedemas, hereditary
injections, subcutaneous
plasma kallikrein
product surveillance, postmarketing
drug interactions
pregnancy
breast feeding
aged
drug evaluation, preclinical
lanadelumab
lanadelumab
antibodies, monoclonal
antibodies, monoclonal

---
Nous contacter.
04/05/2025


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.